Moreover, the 36-month beta value for ADIL is 1.28. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADIL is 3.78M and currently, short sellers hold a 0.23% of that float. On April 22, 2024, ADIL’s average trading volume was 6.36M shares.
ADIL) stock’s latest price update
The stock price of Adial Pharmaceuticals Inc (NASDAQ: ADIL) has dropped by -11.06 compared to previous close of 2.17. Despite this, the company has seen a fall of -17.17% in its stock price over the last five trading days. Invezz reported 2024-04-10 that Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients.
ADIL’s Market Performance
Adial Pharmaceuticals Inc (ADIL) has experienced a -17.17% fall in stock performance for the past week, with a 10.29% rise in the past month, and a 51.37% rise in the past quarter. The volatility ratio for the week is 25.39%, and the volatility levels for the past 30 days are at 19.94% for ADIL. The simple moving average for the past 20 days is 12.95% for ADIL’s stock, with a -29.42% simple moving average for the past 200 days.
Analysts’ Opinion of ADIL
Many brokerage firms have already submitted their reports for ADIL stocks, with Maxim Group repeating the rating for ADIL by listing it as a “Buy.” The predicted price for ADIL in the upcoming period, according to Maxim Group is $5 based on the research report published on October 30, 2018 of the previous year 2018.
ADIL Trading at 18.20% from the 50-Day Moving Average
After a stumble in the market that brought ADIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.21% of loss for the given period.
Volatility was left at 19.94%, however, over the last 30 days, the volatility rate increased by 25.39%, as shares surge +12.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +58.21% upper at present.
During the last 5 trading sessions, ADIL fell by -17.17%, which changed the moving average for the period of 200-days by -65.69% in comparison to the 20-day moving average, which settled at $1.7198. In addition, Adial Pharmaceuticals Inc saw 3.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADIL starting from Schuyler Kevin, who purchase 700 shares at the price of $2.74 back on Sep 29 ’23. After this action, Schuyler Kevin now owns 700 shares of Adial Pharmaceuticals Inc, valued at $1,918 using the latest closing price.
Stock Fundamentals for ADIL
The total capital return value is set at -1.85. Equity return is now at value -208.36, with -144.46 for asset returns.
Currently, EBITDA for the company is -6.89 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
To wrap up, the performance of Adial Pharmaceuticals Inc (ADIL) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
